文献速递肝病

无创检查对门静脉高压的预后评估效能与肝静脉压力梯度相当

Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
PubMed 文献 · J Hepatol · 2024-01-11

该回顾性研究纳入420例代偿期进展性慢性肝病(cACLD)患者,评估无创检查(ANTICIPATE±NASH模型和VITRO)与肝静脉压力梯度(HVPG)对肝失代偿的预后价值。结果显示两者1至2年AUROC与HVPG相似,校正MELD和 albumin 后均可预测首次失代偿,既往切点能准确区分低风险与高风险患者。

要点

  • 在420例cACLD患者中,ANTICIPATE±NASH模型和VITRO对肝失代偿的预后判别力与HVPG相当。
  • HVPG、VITRO和ANTICIPATE±NASH-CSPH概率均独立预测首次肝失代偿。
  • 既往提出的HVPG、VITRO和ANTICIPATE切点能准确区分低风险与高风险患者。

核心结论

  • ANTICIPATE±NASH-CSPH概率和VITRO的预后效能与HVPG相当,支持其用于识别可能从预防首次肝失代偿的药物治疗中获益的患者。

研究设计与样本

  • 回顾性纳入2007年至2022年接受同日HVPG和无创检查评估的cACLD患者(肝硬度测量≥10 kPa),记录肝失代偿的长期随访数据。

主要发现

  • 共纳入420例不同病因的cACLD患者,CSPH患病率为67.6%。
  • 1年和2年肝失代偿累积发生率分别为4.7%和8.0%。
  • HVPG、VITRO和ANTICIPATE±NASH-CSPH概率的1年AUROC为0.683-0.811,2年AUROC为0.699-0.801。
  • 校正MELD评分和白蛋白后,HVPG(aSHR 1.099 [95% CI 1.054-1.150] 每mmHg;p <0.001)、VITRO(aSHR 1.134 [95% CI 1.062-1.211] 每单位;p <0.001)和ANTICIPATE±NASH-CSPH概率(aSHR 1.232 [95% CI 1.094-1.387] 每10%;p <0.001)均预测随访期间首次失代偿。
  • 既往提出的切点(HVPG ≥10 mmHg vs. <10 mmHg、VITRO ≥2.5 vs. <2.5、ANTICIPATE-CSPH概率 ≥60% vs. <60%)均能准确区分肝失代偿风险可忽略与风险较高的患者。

关键数值与推荐

  • HVPG ≥10 mmHg vs. <10 mmHg可区分肝失代偿风险可忽略与风险较高的患者。
  • VITRO ≥2.5 vs. <2.5可区分肝失代偿风险可忽略与风险较高的患者。
  • ANTICIPATE-CSPH概率 ≥60% vs. <60%可区分肝失代偿风险可忽略与风险较高的患者。

临床怎么用

  • 作者认为无创检查应在临床常规中每年应用并更新,以识别短期风险患者,从而识别可能从预防肝失代偿治疗中获益的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-invasive tests to assess the probability of clinically significant portal hypertension (CSPH) - including the ANTICIPATE±NASH models based on liver stiffness measurement and platelet count±BMI, and the von Willebrand factor antigen to platelet count ratio (VITRO) - have fundamentally changed the management of compensated advanced chronic liver disease (cACLD). However, their prognostic utility has not been compared head-to-head to the gold standard for prognostication in cACLD, i.e. the hepatic venous pressure gradient (HVPG). METHODS: Patients with cACLD (liver stiffness measurement ≥10 kPa) who underwent advanced characterization via same-day HVPG/non-invasive test assessment from 2007-2022 were retrospectively included. Long-term follow-up data on hepatic decompensation was recorded. RESULTS: Four hundred and twenty patients with cACLD of varying etiologies, with a CSPH prevalence of 67.6%, were included. The cumulative incidence of hepatic decompensation at 1 and 2 years was 4.7% and 8.0%, respectively. HVPG, VITRO, and ANTICIPATE±NASH-CSPH-probability showed similar time-dependent prognostic value (AUROCs 0.683-0.811 at 1 year and 0.699-0.801 at 2 years). In competing risk analyses adjusted for MELD score and albumin, HVPG (adjusted subdistribution hazard ratio [aSHR] 1.099 [95% CI 1.054-1.150] per mmHg; p <0.001), or VITRO (aSHR 1.134 [95% CI 1.062-1.211] per unit; p <0.001), or ANTICIPATE±NASH-CSPH-probability (aSHR 1.232 [95% CI 1.094-1.387] per 10%; p <0.001) all predicted first decompensation during follow-up. Previously proposed cut-offs (HVPG ≥10 mmHg vs. <10 mmHg, VITRO ≥2.5 vs. <2.5, and ANTICIPATE-CSPH probability ≥60% vs. <60%) all accurately discriminated between patients at negligible risk and those at substantial risk of hepatic decompensation. CONCLUSIONS: The prognostic performance of ANTICIPATE±NASH-CSPH-probability and VITRO is comparable to that of HVPG, supporting their utility for identifying patients who may benefit from medical therapies to prevent first hepatic decompensation. IMPACT AND IMPLICATIONS: Non-invasive tests have revolutionized the diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). However, limited data exists regarding the prognostic utility of non-invasive tests in direct comparison to the gold standard for prognostication in cACLD, i.e. the hepatic venous pressure gradient. In our study including 420 patients with cACLD, the ANTICIPATE±NASH model and VITRO yielded similar AUROCs to hepatic venous pressure gradient for hepatic decompensation within 1 to 2 years. Thus, non-invasive tests should be applied and updated in yearly intervals in clinical routine to identify patients at short-term risk, thereby identifying patients who may benefit from treatment aimed at preventing hepatic decompensation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jachs M, Hartl L, Simbrunner B, et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. J Hepatol. 2024. PMID: 38218352. doi:10.1016/j.jhep.2023.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。